Connect with us

Technology

Lucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Published

2 years ago

on

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over 600,000 United States based patients; approximately one-third are tissue samples.  Ovation plans to continue expanding the biobank with the addition of 200,000 + patient samples per monthOvation’s biobank includes tissue, blood and other sample types from patients with diseases of current discovery and development interest including inflammatory bowel disease (IBD), liver disease, chronic kidney disease (CKD), cardio-metabolic/GLP-1, various types of cancers, and neurodegenerative diseases such as Alzheimer’s diseaseThe Company plans to produce a database of linked omics and patient/clinical data for each diseaseThe merger combines teams with deep domain expertise in human genetics, disease pathogenesis, and pathology

NEW YORK, Sept. 5, 2024 /PRNewswire/ — Ovation and PDTx today announced the completion of their merger.  The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology and imaging, AI/ML and data commercialization.  The Company’s enhanced platform capabilities and data libraries can drive deeper insights into cellular biology and gene expression for research, drug development, and clinical decision making and across a broad range of diseases.

“We believe the two companies are deeply complementary and will provide our customers with best-in-class, diverse multiomics data,” said Curt Medeiros, CEO of Ovation. “These one-of-a-kind data sets will combine Ovation’s DNA and RNA sequencing of patient samples in a given disease state with PDTx’s mapping of cellular footprints, spatial context, immune system functionality and markers, as well as clinical pathology imaging.  This will help drive our client’s R&D efforts, from target and biomarker discovery, through optimized clinical trial enrollment.”

Human genomic data has become an increasingly important tool in disease target and biomarker discovery. By analyzing an individual’s genetic makeup, especially in relation to clinical progression and outcomes, researchers are able to better understand the underlying causes of diseases and identify potential therapeutic targets and biomarkers. Ovation is building the world’s broadest commercially available human genomic dataset that brings together whole genome sequences with longitudinal clinical records at the patient level (“clinic-genomics data”) to address the speed and cost at which new research efforts can be powered by human genomics. This clinic-genomics database will enable a depth and breadth of analytics not currently possible due to the scale, continuous flow of new patient samples, and diversity of patients.

“The Ovation and PDTx teams are energized and have been collaborating for the past year to position our first proof-of-concept programs in IBD and prostate cancer for groundbreaking results,” said Patrick Gallagher, CEO of PDTx. “The in-house biobank will allow the team to accelerate data generation and more fully leverage the PDTx platform’s high dimensional multiomic modalities that characterize cellular status. This includes changes in and predictiveness of proteins, glycans, metabolites, and cell-cell spatial relationships that can drive discovery and correlations with pathological features of disease severity, progression and therapeutic response.”

PDTx has developed a disease-agnostic platform to analyze data collected across multiple high-dimensional imaging technologies to discover new drug development targets and identify critical biomarkers of disease progression and therapeutic response. The PDTx platform provides the ability to visualize the presence, concentration, and distribution of molecules and analyze intra- and inter-molecular and phenotypic single-cell relationships and their impact on morphology. Ovation will retain PDTx’s exclusive global license for the platform and its intellectual property from Massachusetts General Hospital (MGH) and the Vaccine and Immunotherapy Center (VIC) at (MGH).

“We are incredibly excited to collaborate with the research team at Ovation,” said Mark Poznansky, M.D., Ph.D, scientific co-founder of PDTx and director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital. “Connecting genetic data with cellular, structural, and chemical details of tissue affected by IBD or prostate cancer can lead to important translational medical progress. For example, our combining a multiomics platform that provides information on both the genetic and protein signature in blood as well the location of specific chemicals and cells within a tissue, can help identify new sets of biomarkers that are potentially impactful diagnostically and prognostically as well as revealing of new disease-related therapeutic targets.”  

By combining imaging and sequencing, state-of-the-art multiomics can map the location of specific proteins and chemical products in tissues and identify the location and the presence of these chemical entities. This provides a critical perspective about the cellular microenvironment and inter-cellular interactions in biopsies of diseased tissue.

“This merger leverages a platform with unparalleled scalability to create a leading multiomics company with, ultimately, unparalleled data access and richness,” said James Ahern, Managing Partner of Laidlaw & Company and co-founder of Lucius Partners. “The unique capabilities it creates will speed the development of cost-saving, efficacious, patient-driven solutions for the healthcare industry and continue to enhance shareholder value.  We greatly appreciate our shareholder’s support of this important vision.”

About Ovation

Ovation is an omics data company committed to accelerating the development of precision medicine. Ovation provides life sciences R&D teams access to high-quality omics data linked to rich, longitudinal clinical data, across therapeutic areas, at population scale. Ovation’s data increases the probability of success for drug discovery by enabling the identification and validation of biomarkers and therapeutic targets. The company has an extensive biobank of more than 1.6 million geographically diverse, consented biospecimens from over 625,000 unique patients. For more information, visit www.ovation.io or follow the company on LinkedIn.

About PD Theranostics

PDTx is a data-driven healthcare company focused on leveraging proprietary workflows and using multi-parameter imaging-based methodologies to generate robust, one-of-a-kind multi-omic cellular biology-based databases for numerous disease states. Our proprietary imaging processes, (developed by scientific co-founders of PDTx and the Vaccine and Immunotherapy Center, MGH, Drs. Patrick Reeves, Ruxandra Sîrbulescu, and Mark Poznansky), driven by a multi-omics approach, will generate spatial roadmaps of human cancers and other diseases, leading to unparalleled data richness and depth. Through our ability to map tissue structures and immune populations, we believe we could more clearly define disease stage, and likelihood of disease progression, and identify the most efficacious treatment regimens for each patient.

Contact Information

Patrick Gallagher, CEO 
PD Theranostics, Inc. 
Managing Partner 
Lucius Partners, LLC 
pgallagher@luciuspartnersllc.com

James Ahern, Founder
Lucius Partners, LLC 
jahern@luciuspartnersllc.com

Forward-Looking Statement

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the Ovation Platform and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based on Ovation’s current expectations and various assumptions. Ovation believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Ovation may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions. Consequently, forward-looking statements should be regarded solely as Ovation’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Ovation cannot guarantee future results, events, levels of activity, performance or achievements. Ovation does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucius-partners-portfolio-company-pd-theranostics-completes-its-merger-with-ovationio-creating-a-multiomic-data-company-which-owns-a-unique-population-scale-biobank-of-disease-specific-biospecimens-302239631.html

SOURCE Lucius Partners, LLC

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

EA Automatic Announces Next Generation Intelligent Trading Solutions Built for Performance, Precision, and Long-Term Growth

Published

10 seconds ago

on

April 29, 2026

By

Redefining algorithmic trading through personalized strategies, AI-enhanced systems, and expert human oversight

LONDON, April 29, 2026 /PRNewswire/ — In today’s fast-moving financial landscape, where market conditions shift in seconds and opportunities are often measured in milliseconds, traders and investors are increasingly turning to technology to stay competitive. EA Automatic has officially announced the launch and expansion of its intelligent automated trading solutions, designed to deliver precision, adaptability, and performance without sacrificing strategic control.

Positioned at the intersection of advanced technology and real-world trading expertise, EA Automatic is setting a new standard in algorithmic trading. The company offers more than just trading bots. It delivers fully integrated trading systems built around the individual goals, risk tolerance, and long-term ambitions of each client.

At its core, EA Automatic is driven by a simple but powerful philosophy. Automation alone is not enough. True success in trading comes from combining intelligent systems with informed human decision-making. This belief has shaped every aspect of the company’s platform, resulting in solutions that go beyond execution to deliver meaningful, consistent performance.

A Personalized Approach to Automated Trading

One of the defining features of EA Automatic is its commitment to customization. In an industry where many platforms rely on rigid, one-size-fits-all models, EA Automatic takes a fundamentally different approach.

Every investor is unique. Financial goals, risk appetite, and investment timelines vary widely from one individual to another. Recognizing this, EA Automatic designs and deploys trading strategies that are tailored specifically to each client’s profile.

Whether the objective is steady monthly income, capital preservation, or aggressive growth through higher risk strategies, the platform adapts accordingly. By aligning each system with clearly defined goals, EA Automatic ensures that clients are not simply participating in the market but doing so with purpose and direction.

This level of personalization is further enhanced through smart diversification. Rather than relying on a single strategy or market condition, EA Automatic spreads risk intelligently across multiple approaches. This creates a more stable trading environment and helps protect capital even during periods of volatility.

Advanced Technology Built on Real Trading Insight

The EA Automatic platform is the result of more than two and a half years of focused development. During this time, the company has worked to integrate cutting-edge artificial intelligence with practical trading knowledge gained from real market experience.

The result is a system that does not rely solely on algorithms but uses AI to enhance decision-making. Automation handles the speed and efficiency required for modern trading, executing trades with precision and consistency. At the same time, human expertise remains a critical component of the process.

A dedicated team of professional traders continuously monitors performance, evaluates market conditions, and adjusts strategies as needed. This dynamic approach allows the platform to respond to changes in real time while maintaining a structured and disciplined trading framework.

By combining machine efficiency with human oversight, EA Automatic delivers a balanced solution that minimizes emotional decision-making while retaining the flexibility needed to adapt in unpredictable markets.

A Strong Focus on Risk Management and Stability

In an environment where many trading services focus on rapid gains and unrealistic promises, EA Automatic takes a more disciplined and transparent approach. The company places risk management at the center of its strategy development process.

Rather than promising overnight success, EA Automatic emphasizes consistency, structure, and long-term sustainability. Every system is built on proven methodologies designed to reduce unnecessary exposure and protect client capital.

Key risk management principles are embedded into each strategy, including controlled position sizing, diversified asset allocation, and continuous performance monitoring. These elements work together to create a trading experience that prioritizes stability without sacrificing growth potential.

By removing emotional bias and guesswork from the equation, EA Automatic enables clients to engage with the market in a more rational and controlled manner. This structured approach is particularly valuable in volatile conditions, where impulsive decisions can lead to significant losses.

Ongoing Support and a Clear Path to Growth

EA Automatic understands that successful trading is not just about technology. It is also about support, guidance, and transparency. Clients are not left to navigate the platform on their own. Instead, they gain access to a complete trading ecosystem designed to support long-term success.

From initial onboarding to ongoing strategy adjustments, the EA Automatic team works closely with clients to ensure that their systems remain aligned with their evolving goals. This continuous support helps build confidence and allows investors to focus on growth rather than day-to-day market fluctuations.

The company’s commitment to clarity and communication further strengthens this relationship. Clients receive insights into how their strategies operate, what factors influence performance, and how adjustments are made in response to changing conditions.

This level of engagement transforms the trading experience from a passive process into a guided journey, where clients are empowered with both tools and understanding.

Redefining What Automated Trading Means

As automation becomes increasingly common in the financial world, the distinction between basic tools and intelligent systems is becoming more important. EA Automatic is leading this shift by redefining what automated trading can and should be.

Instead of offering standalone bots, the company delivers comprehensive solutions that integrate strategy, technology, and expertise. This approach ensures that clients are not simply executing trades but participating in a structured and well-managed investment process.

By focusing on personalization, advanced technology, and disciplined risk management, EA Automatic is creating a model that is both scalable and sustainable. It is a model designed not for short term speculation but for long term financial growth.

About EA Automatic

EA Automatic is a London-based financial technology company specializing in intelligent automated trading solutions. With a focus on combining artificial intelligence with real trader expertise, the company develops customized algorithmic strategies tailored to individual investment goals and risk profiles.

Built over more than two and a half years of development, the EA Automatic platform emphasizes precision, adaptability, and risk management. Clients benefit from continuous monitoring, expert oversight, and a structured approach designed to deliver consistent results over time.

EA Automatic is committed to helping investors navigate the complexities of modern financial markets with confidence, clarity, and control.

Contact:
EA Automatic
Website https://ea-automatic.com
Email support@ea-automatic.com

Watch the video: Clinton & David Interview [EA Automatic Review]

Photo – https://mma.prnewswire.com/media/2969575/EA_Automatic.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ea-automatic-announces-next-generation-intelligent-trading-solutions-built-for-performance-precision-and-long-term-growth-302758028.html

SOURCE EA Automatic

Continue Reading

Technology

New Blog Series from Commercial Credit Group (CCG) Helps Businesses Make Smarter Equipment Financing Decisions for Long-Term Growth

Published

12 seconds ago

on

April 29, 2026

By

CHARLOTTE, N.C., Apr. 29, 2026 /PRNewswire/ — Drawing on more than two decades of working alongside equipment owners across industries and economic cycles, Commercial Credit Group (CCG) has launched a new thought leadership series focused on the real‑world lessons that shape resilient, growth‑oriented businesses.

The five‑part blog series, Lessons From Over 20 Years of Equipment Financing, draws from the experiences of CCG’s leadership team as they’ve partnered with equipment owners across industries and economic cycles. Rather than focusing on short-term market trends, the series delivers real-world insights that help companies evaluate financing strategies, avoid common pitfalls, and align equipment investments with long-term business goals.

For companies considering equipment purchases, expansion, or refinancing, the series provides perspective on:

How successful equipment owners structure financing decisions to support cash flow and growth

Common mistakes that can limit flexibility or create risk over time

Proven principles that hold up across changing markets, interest rate environments, and business cycles

“After more than 20 years of financing equipment through multiple market cycles, we’ve seen firsthand that while the market evolves, the fundamentals of lending and responsible growth haven’t changed,” said CEO and founder, Dan McDonough. “This series is designed to help equipment-focused businesses make smarter decisions today that still serve them years down the road.”

The series is particularly relevant for owners, executives, and finance leaders in construction, transportation, manufacturing, and waste industries who want to better understand how financing choices impact operational flexibility and long-term performance.

The Lessons From Over 20 Years of Equipment Financing series is now available on the CCG website. Readers are encouraged to explore the full series to gain practical insights drawn directly from decades of real-world financing experience.

About Commercial Credit Group Inc.:

Commercial Credit Group Inc., a wholly owned subsidiary of Commercial Credit, Inc., is an independent commercial finance company that provides equipment loans and leases to small and mid-sized businesses in the construction, fleet transportation, machine tool, manufacturing, and waste industries. The company’s sales force is located throughout North America. Since its inception in 2004, CCG has originated over $8 billion in equipment loans and leases. CCG is headquartered in Charlotte, NC. For more information, please visit www.commercialcreditgroup.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-blog-series-from-commercial-credit-group-ccg-helps-businesses-make-smarter-equipment-financing-decisions-for-long-term-growth-302757985.html

SOURCE Commercial Credit Group Inc.

Continue Reading

Technology

Frost & Sullivan Institute Announces Visionary Leadership Best Practices Recognition and This Year’s Honorees

Published

14 seconds ago

on

April 29, 2026

By

SAN ANTONIO, April 29, 2026 /PRNewswire/ — The Frost & Sullivan Institute (FSI) is pleased to unveil this year’s recipients of the Visionary Leadership Best Practices Recognition. These individuals exemplify purpose-driven leadership, bold innovation, and measurable impact aligned with FSI’s mission to inspire solutions that advance Education, Environment, Healthcare, Human Rights, Infrastructure, Security, and Economic Progress.

These distinguished leaders have demonstrated exceptional commitment to creating long-term, systemic impact, whether through pioneering environmental solutions, transforming access to education or healthcare, improving social infrastructure, or advancing community well-being.

“At the Frost & Sullivan Institute, we believe change accelerates when we recognize and celebrate those who lead with courage and clarity. This year’s honorees remind us that visionary leadership is not just about bold ideas but about creating meaningful outcomes that uplift people and communities,” said David Frigstad, Executive Director, Frost & Sullivan Institute.  

Our evaluation process is grounded in a best practices framework, assessing nominees across three parameters namely Impact, Innovation, and Implementation. A panel of experts conducts a structured review, followed by benchmarking and consensus-building to ensure fairness, credibility, and alignment with FSI’s seven global priority areas. The final honorees represent leaders whose work shows clear, sustained, and scalable impact.

The list of visionary leaders for 2026 includes:

Aadith Moorthy

Ai-jen Poo

Aki Ra

Akshay Saxena

Alex Kelly

Alex Stephany

Aline Sara

Amira Yahyaoui

Ana Bella Estévez Jiménez de los Galanes

Andrew Bastawrous

Anna Luísa Beserra Santos

Anna‑Lena von Hodenberg

Anshu Gupta

Anshu Sharma

Asma Mansour

Atul Gawande

Barbara Mutabazi

Barbarita Lara

Blaise Judja-Sato

Boyan Slat

Brigitha Faustin

Bruce Schneier

Catalina Escobar

Colette Pichon Battle

Connor Schoen

Diana Johanna Willemina Theresia Nijboer

Dr Mihai Ranete

Dr. Abhay Bang

Dr. Alex Dehgan

Dr. Devi Shetty

Dr. Katrin Schuhen

Dr. Peter Rohloff

Dr. Rebecca Onie

Dr. Rebecca Richards-Kortum

Dr. Tan See Leng

Dr. Tererai Trent

Esra’a Al Shafei

Esther Kimani

Esther Olalude

Fábio Luiz de Oliveira Rosa

Faith Kuya

Fatemah (Fatema) Alzelzela

Feliciano Reyna

Gillian Henker

Harish Hande

Hasina Kharbhih

HH Sheikha Intisar AlSaba

Irene Mbari‑Kirika

Jairo Trad

Jason Ballard

Javier Goyeneche

Jay Chaudhry

Jayshree Satpute

About Frost & Sullivan Institute

The Frost & Sullivan Institute (FSI) is a non-profit organization dedicated to utilizing business practices to address global priorities. The genesis of the institute goes back to the vision of either creating or becoming part of a solution that addresses threats to humanity. The Institute has identified strategic imperatives for transformation and believes that we can truly accelerate innovation to zero. To learn more about FSI, visit www.frostandsullivaninstitute.org

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Media Contact:

Bivechana Gautam
Email: Bivechana.gautam@frost.com

Related Links:
www.frost.com
www.frostandsullivaninstitute.org

View original content:https://www.prnewswire.com/news-releases/frost–sullivan-institute-announces-visionary-leadership-best-practices-recognition-and-this-years-honorees-302758010.html

SOURCE Frost & Sullivan

Continue Reading

Trending